When Access Creates Evidence: Real‑World Data from Expanded Access Programs

  • Realworld evidence generated through these programs that has informed regulatory decisionmaking, contributing to EMA scientific advice discussions and, in specific cases, resulted in FDA labeling indications and marketing authorizations
  • This session will focus on the types of approaches and real regulatory results